SEC Comment Letter 0000000000-23-011612 to Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics, Inc.
Date: Oct. 24, 2023 · CIK: 0001636282 · Accession: 0000000000-23-011612

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37722

Date

October 24, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Spyre Therapeutics, Inc.

Letter

United States securities and exchange commission logo October 24, 2023 Cameron Turtle, DPhil Chief Operating Officer Aeglea BioTherapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 Re:Aeglea BioTherapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed August 8, 2023 File No. 001-37722 Dear Cameron Turtle: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden C. Berns

Show Raw Text

United States securities and exchange commission logo
October 24, 2023
Cameron Turtle, DPhil
Chief Operating Officer
Aeglea BioTherapeutics, Inc.
221 Crescent Street
Building 23, Suite 105
Waltham, MA 02453
Re:Aeglea BioTherapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed August 8, 2023
File No. 001-37722
Dear Cameron Turtle:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Branden C. Berns

SecProbe.io